iCTC药物耐药性(CDR)体外检测用于评估上皮性卵巢癌患者现有疗法的研究
本研究开发了基于患者来源培养的侵袭性循环肿瘤细胞(iCTC)的药物耐药性(CDR)检测,使用紫杉醇-卡铂及八种其他上皮性卵巢癌药物在患者用浓度下进行检测。结果显示CDR评分高于100表示敏感、低于100表示耐药,且患者治疗史和随访证实iCTC敏感时处于缓解,耐药时处于复发。作者认为需进一步研究该检测在治疗前选药中的应用。
要点
- CDR评分高于100表示对药物敏感,低于100表示耐药。
- 6例初治前样本中5例对紫杉醇-卡铂敏感(>20 iCTC/>111 CDR),1例耐药(40 iCTC/23 CDR)。
- 治疗后6例中4例iCTC降至0且CDR>153提示敏感,2例iCTC>45且CDR<85提示耐药。
核心结论
- 作者认为需进一步研究CDR检测以检验其在治疗前为患者选择药物中的用途。
研究设计与样本
- 使用紫杉醇-卡铂及八种其他上皮性卵巢癌药物在患者用浓度下进行CDR检测。
- 血液样本来自6例初治前患者、1例复发患者、6例化疗期间及之后患者和2例良性疾病患者作为操作对照。
主要发现
- 6例初治前样本中5例对紫杉醇-卡铂敏感(>20 iCTC/>111 CDR),1例耐药(40 iCTC/23 CDR)。
- 复发样本为58 iCTC/5 CDR,提示耐药。
- 治疗后6例中4例iCTC降至0且CDR>153提示敏感,2例iCTC>45且CDR<85提示耐药。
- 患者治疗史和随访证实iCTC对紫杉醇-卡铂敏感时处于缓解,耐药时处于复发。
关键数值与推荐
- CDR评分高于100表示敏感,低于100表示耐药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究CDR检测以检验其在治疗前选药中的用途。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
GOALS: Management of epithelial ovarian cancer (EOC) could use serial measurements of invasive circulating tumor cells (iCTCs) for monitoring therapeutic response and early detection of disease progression/recurrence. Goals of this study are to develop an iCTC drug resistance (CDR) assay and to evaluate clinical significance of patient-derived, cultured iCTCs in selecting available therapies. METHODS: The CDR assay using Taxol-Carboplatin and eight other EOC drugs at the concentration used for patients was performed. Blood was donated by six patients before primary Taxol-Carboplatin chemotherapy, one recurrent patient, six patients during and after their course of chemotherapy, and two patients with benign disease for procedure control. CDR score above and below 100 indicates sensitivity and resistance, respectively, to that drug. RESULTS: Five of six pre-therapy samples had >20 iCTCs/>111 CDR for Taxol-Carboplatin sensitivity, and one had 40 iCTCs/23 CDR for resistance. The recurrent sample had 58 iCTCs/5 CDR for resistance. Four of six post-therapy patients had iCTCs decreased to 0/>153 CDR indicating sensitivity, while two patients had >45 iCTCs/<85 CDR indicating resistance. The patients' treatment history and follow-up confirmed that patients were in response or remission when iCTCs were sensitive to Taxol-Carboplatin, and patients were in relapse or recurrence when iCTCs were resistant to Taxol-Carboplatin. CONCLUSION: Further investigation on the CDR assay is warranted to examine its use in selecting drugs before treating a patient.
引用
- Pearl ML, Dong H, Zhao Q, et al. iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer. Gynecol Oncol. 2017. PMID: 28830645. doi:10.1016/j.ygyno.2017.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。